Educational only — not medical advice. If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources. Under construction and review—see the updates log.

prazosin

Adjunctive therapy

Brand: MINIPRESS

Published 2025-12-21 · Last reviewed 2025-12-28 · 4 references

Content sourced from FDA labeling (DailyMed) and peer-reviewed literature.

Print sheet Review evidence

At a glance

Class: Adjunctive therapy·Typical dose: PTSD nightmares (off label): start 1 mg at bedtime; titrate gradually (often in 1 mg increments) based on nightmare frequency and tolerability.·Half-life: Single-dose range 2–3 h·LAI available: No

Class: Adjunctive therapy
Typical dose: PTSD nightmares (off label): start 1 mg at bedtime; titrate gradually (often in 1 mg increments) based on nightmare frequency and tolerability.
Half-life: Single-dose range 2–3 h
LAI available: No

Quick answers

What is prazosin?: Prazosin (brand Minipress) is an alpha-1 blocker approved for hypertension and commonly used off label to reduce PTSD-related nightmares and sleep disruption.
What is MINIPRESS?: MINIPRESS is a brand name for prazosin.
What is MINIPRESS (prazosin) used for?: Label indications include: Hypertension (label); commonly used off label for PTSD-related nightmares.
What drug class is MINIPRESS (prazosin)?: Alpha-1 Blocker.
What is the mechanism of action of MINIPRESS (prazosin)?: Alpha-1 adrenergic antagonist; reduces sympathetic tone (vasodilation).
What strengths does MINIPRESS (prazosin) come in?: Capsules: 1 mg, 2 mg, 5 mg.

General information

Prazosin is an alpha-1 adrenergic antagonist approved for hypertension and commonly used off label to reduce PTSD-related nightmares and sleep disruption.

Evidence is mixed across populations and trials, so treat it as a symptom-targeted adjunct with explicit reassessment milestones rather than an indefinite prescription.

Prazosin is most useful when nightmares are a prominent driver of sleep disruption and baseline blood pressure can tolerate an alpha-1 blocker; document baseline vitals, define success metrics (nightmare frequency, sleep continuity), and stop rather than continuing indefinitely if benefit is unclear.

The prazosin compare view, prazosin evidence feed, and prazosin print page can support aligning sleep symptom goals with safety planning.

U.S. approvals

Hypertension

Formulations & strengths

Capsules: 1 mg, 2 mg, 5 mg.

Generic availability

Widely available generically.

Key early risks are first-dose syncope and orthostatic hypotension; start low at bedtime and titrate slowly, especially when combined with other blood-pressure-lowering medications. Because evidence is mixed, build in a reassessment milestone (for example after titration to a tolerated target dose) and taper off if nightmares do not clearly improve.

View labelExact

Mechanism of action

Refer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.

Selective alpha-1 adrenergic receptor antagonism reduces sympathetic tone and peripheral vascular resistance.

Central noradrenergic modulation is the proposed mechanism for nightmare reduction in PTSD.

Alpha-1 blockade can reduce trauma-related adrenergic arousal at night, but clinical response is variable; pair with trauma-focused therapy and sleep interventions rather than using prazosin as a standalone PTSD strategy.

Alpha-1 antagonism (vasodilation; orthostatic hypotension risk).

Metabolism & pharmacokinetics

Peak plasma concentrations occur at ~3 hours after oral administration (label).
Plasma half-life is ~2–3 hours (label).
Extensively metabolized; excreted mainly via bile and feces (label).
Despite a short plasma half-life, hypotension and dizziness can persist, especially early in titration or when combined with other blood-pressure-lowering agents.

Dosing & administration

PTSD nightmares (off label): start 1 mg at bedtime; titrate gradually (often in 1 mg increments) based on nightmare frequency and tolerability.
If doses are missed for several days, consider restarting at a low dose and retitrating to reduce first-dose syncope risk.
Do not “catch up” missed doses; prioritize safety, retitrate as needed, and reassess alternative nightmare/sleep strategies if titration is limited by hypotension.
Daytime dosing may be used for hyperarousal symptoms, but increases hypotension risk and requires close monitoring.
If daytime dosing is used, start even lower and monitor standing blood pressure and falls risk; many patients tolerate bedtime-only dosing more safely.

Monitoring & labs

Check blood pressure (including orthostatic vitals) during initiation and after dose increases; counsel hydration and slow positional changes.
Reassess falls risk and co-prescribed sedatives/antihypertensives; adjust titration speed accordingly.
Define a reassessment milestone for nightmare response; taper and stop if benefit is unclear after an adequate trial.
If doses are missed for several days, restart low and retitrate to reduce first-dose syncope risk.

Sources: FDA/DailyMed label; meta-analyses and guideline reviews.

Adverse effects

FDA boxed warnings

Common side effects (≥10%)

Orthostatic hypotension / syncope: Highest risk at initiation and after dose increases; counsel hydration and slow positional changes.
Dizziness / fatigue: Common during titration; reassess fall risk and co-prescribed sedatives.
Headache: Usually dose-related; consider slower titration.
Nasal congestion: Can occur due to vasodilation; monitor tolerability.

Other notable effects

Hypotension risk increases with dehydration, acute illness, or other antihypertensives.
Rare priapism has been reported with alpha-1 blockers; counsel to seek urgent care for prolonged erections.

Interactions

Additive hypotension with other antihypertensives, nitrates, or PDE5 inhibitors (sildenafil/tadalafil).
Antipsychotics with orthostatic liability (clozapine, quetiapine) can compound dizziness and falls.
Alcohol, sedatives, and dehydration can compound dizziness and syncope; provide harm-reduction counseling and reassess during intercurrent illness.

Other useful information

Define the target symptom and document a titration and reassessment plan.
Pair with PTSD-first-line treatments and sleep interventions; avoid treating prazosin as a standalone PTSD strategy.
If the response is unclear after a reasonable titration window, taper and discontinue rather than continuing indefinitely.
Track nightmares and sleep quality with brief check-ins (sleep diary or weekly rating); if there is clear benefit, periodically reassess whether the dose can be reduced while maintaining symptom control.

References

Related hubs:SMI toolkit·Support resources